GenVec, Inc. reported today that the U.S. Food and Drug Administration (FDA) has approved GenVec’s TNFerade™ for Fast Track development in the treatment of locally advanced pancreatic cancer. TNFerade™ is designed to stimulate the production of immune system proteins with anti-cancer properties that are injected into tumors. GenVec is developing TNFerade™ for use in combination with other tools such as radiation and chemotherapy for the treatment of various cancers.

TNFerade™ qualifies for Fast Track status because GenVec provided the FDA with evidence that TNFerade™ may have potential to improve the survival rate of patients suffering from pancreatic cancer. The FDA grants Fast Track designation to drugs that are designed to treat life-threatening conditions and that have a proven potential to address an unmet medical need.

Fast Track designation only applies to situations where a developmental stage drug is used to treat one specific

...

Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with

...

Our Director of Marketing’s Grandfather died of a massive brain tumor when she was only about a year old. His last days were a combination of comatose and automatic speaking. He recited every line that he had ever spoken on stage (he was in the entertainment industry). Although she doesn’t remember it, it was very traumatic for her family.

Recurrent Glioblastoma Multiforme is the most common type of malignant primary brain tumor in adults. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation and chemotherapy. Additionally, Brain stem cell cancer is the most lethal cancer in children, with a survival rate of less than one year after diagnosis.

NeoPharm’s agreement with NINDS will serve as another step in pursuing the validation of the company’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (“IL-13”) and its impact on possibly

...

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company focused on the development and commercialization of innovative medical treatments utilizing their proprietary polymer-based drug delivery systems.

The company’s proprietary Biochronomer™ technology, featuring bioerodible polymers intended to create controlled-release pharmaceuticals that improve treatments for diseases or health-threatening conditions, is their primary focus as they continue to advance the technology. The company’s lead product candidate is APF530, which is currently in a pivotal Phase III clinical trial for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting, or CINV.

The company has made significant investments in the development of their bioerodible drug delivery technologies, which have produced tangible results. Specifically, A.P. Pharma has developed a broad family of polymers consisting of unique attributes referred to as poly (ortho esters), under the trade name Biochronomer. This technology has been designed for use in drug delivery applications

...

Eli Lilly and Company (LLY) is a global healthcare company with core products in a number of primary-care pharmaceutical markets. The leading product is Zyprexa, a treatment for schizophrenia and bipolar disorder. The company's other leading drugs include Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Byetta (type-II diabetes), Cialis (erectile dysfunction), Strattera (ADHD), and Alimta (chemotherapy).The company is entering a challenging period, brought about by recent pipeline disappointments, most notably uncertainty surrounding antiplatelet drug Prasugrel. Although we believe the underlying fundamentals of the company remain solid, the recent pipeline setbacks and lack of clarity surrounding prasugrel will likely limit the upside to the stock. We also believe that sales of Zyprexa will begin to decline in 2008 as generic Risperdal eats into market share. We see little movement in the stock until the above issues are addressed. We rate the shares a Hold with ...

A cancer diagnosis is devastating, and oftentimes the treatment following such diagnosis can be just as mentally and physically debilitating. The majority of patients receiving treatment experience some degree of emesis, or nausea and vomiting, associated with chemotherapy. The prevention and control of emesis is very important for the patient, and chemotherapy patients are typically administered an anti-emetic prior to treatment.

Specialty pharmaceutical company A.P. Pharma Inc. (Nasdaq: APPA) today announced positive results from its pivotal phase III study that compares the efficacy of the company’s lead product, APF530, with Aloxi for the prevention of emesis, also known as chemotherapy-induced nausea and vomiting (CINV).

The phase III trial is based on the participation of 1,395 patients, treated at 103 centers in the United States, Poland and India. The patients were classified according to their level of emetogenic chemotherapy to demonstrate the safety and efficacy of APF530.

According to the

...

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, announced that it has completed its acquisition of Innovive Pharmaceuticals, Inc. The acquired Innovive portfolio includes four clinical-stage oncology drug candidates, including North American and European rights to develop tamibarotene, which is already approved in Japan for the treatment of relapsed Acute Promyelocytic Leukemia (APL)

CytRx purchased Innovive for 2.6 million shares of CytRx common stock, about $18.3 million of “future performance-based milestone earn-outs”, and the assumption of Innovive’s liabilities. Innovive shareholders approved the deal Sept. 19.

“In acquiring Innovive, CytRx’s objective was to create a balanced business model, with the potential for near-, medium-, and long-term revenue generation,” a company news release states.

Tamibarotene, now in the middle of FDA studies, is considered by the company to have near-term revenue potential. Likely medium-term revenue generating products include molecular chaperone amplifiers arimoclomol and iroxanadine, which could be used to combat ALS and

...

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, announced that it has completed its acquisition of Innovive Pharmaceuticals, Inc. The acquired Innovive portfolio includes four clinical-stage oncology drug candidates, including North American and European rights to develop tamibarotene, which is already approved in Japan for the treatment of relapsed Acute Promyelocytic Leukemia (APL)

CytRx purchased Innovive for 2.6 million shares of CytRx common stock, about $18.3 million of “future performance-based milestone earn-outs”, and the assumption of Innovive’s liabilities. Innovive shareholders approved the deal Sept. 19.

“In acquiring Innovive, CytRx’s objective was to create a balanced business model, with the potential for near-, medium-, and long-term revenue generation,” a company news release states.

Tamibarotene, now in the middle of FDA studies, is considered by the company to have near-term revenue potential. Likely medium-term revenue generating products include molecular chaperone amplifiers arimoclomol and iroxanadine, which could be used to combat ALS and

...

As the market has been pretty focused on whatÂ’s going on with the financial sector over the past week, we donÂ’t want to lose sight of healthcare and whatÂ’s going on there. We are joined by Zacks senior drug industry analyst Jason Napodano, CFA for his outlook on the industry.

Given the challenges in the market right now, are you seeing areas to invest in pharma / biotech?

Well, that’s a good question Mark, and the answer is absolutely we are. The ole “baby and bathwater” move seems to be the prevailing scenario in the market right now. But, I think things should settle down soon, so let’s talk about two different strategies that we have right now for investors looking to put money to work in healthcare.

The first is the long-term, big, safe, blue-chip strategy. Here I really would recommend Abbott Labs (ABT).

...

Millennium Biotechnologies Group, Inc, (OTCBB: MBTG) announced that renowned non-alcoholic beverage industry veteran Ken Sadowsky has joined its board of directors. Sadowsky was also a principal in Atlas Distributing of Auburn, Mass. for many years, where he made his name in the industry.

Sadowsky served on the board of directors of Energy Brands, Inc., makers of Glaceau, VitaminWater, SmartWater and FruitWater, from 2000 to 2006. Glaceau was later was sold to Coca Cola for $4.1 billion.

He is currently the executive director of NIDA, an association of independent distributors from Maine to New Jersey. This group is different from the government group NIDA, National Institute on Drug Abuse.

“As a prominent beverage distributor in the northeast,” a Millennium Biotechnologies news release stated, “he has been credited for foreseeing the market shift away from carbonated beverages with his early adoption of such brands as Snapple Beverages and SoBe.”

“We are actively restructuring our board of

...